Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Omalizumab showed potential benefit in severe COVID-19, but this study found no significant changes in measured serum cytokines. Further research is needed to understand how omalizumab works against COVID-19.
Area Of Science
- Immunology
- Virology
- Pharmacology
Background
- The CIAO trial indicated omalizumab may benefit severe COVID-19 patients.
- The precise mechanism of omalizumab's effect in COVID-19 remains undetermined.
Purpose Of The Study
- To longitudinally evaluate omalizumab's impact on serum cytokines in CIAO trial participants.
- To elucidate the mechanism of action for omalizumab in severe COVID-19 treatment.
Main Methods
- Blood samples were collected from 19 patients (9 omalizumab, 10 placebo) on days 0, 2, 7, and 14.
- Analyzed 25 inflammatory cytokines and mast cell activation markers.
- Used generalized linear mixed-effects models and mixed-effects logistic regression for analysis.
Main Results
- Monokine induced by gamma interferon was associated with severe COVID-19 (OR=1.06, p=0.043).
- Omalizumab treatment significantly reduced interleukin-15 (p=0.048) and macrophage inflammatory protein-1 (p=0.010) levels.
- These biomarker changes were not statistically significant after adjusting for multiple testing.
Conclusions
- Omalizumab's potential benefit in COVID-19 might not be mediated by the measured serum biomarkers.
- The study's small sample size limits definitive conclusions.
- Further investigation is required to fully understand omalizumab's mechanism in COVID-19.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...